<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-17-02-2026-shutterstock_2249605625-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-17-02-2026-shutterstock_2249605625-430x241.jpg"/></p>
<p>兩家公司共同的目標是提供創新治療方案，以改善患有婦科疾病女性的生活質量。圖片來源：Peakstock / Shutterstock.com。</p>
<p>帝人制藥與總部位於東京的 Aska Pharmaceutical 簽署了聯合研究協議，旨在開發針對婦科疾病的小分子藥物候選物。</p>
<p>此次合作旨在加速早期藥物發現，專注於創新療法，利用帝人制藥在計算機輔助藥物設計（CADD）和人工智能方面的專業知識。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - GSK-4381562 在子宮內膜癌中的應用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - INCB-123667 在子宮內膜癌中的應用</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>根據協議，兩家公司將專注於識別與特定分子靶點相互作用的 “命中” 化合物。</p>
<p>這些初步化合物將進一步優化，以確定潛在藥物開發所需的有效性、藥代動力學特性和安全性。</p>
<p>帝人制藥通過提高模擬準確性和預測建模，推進其藥物候選物發現過程，從而建立一個縮短時間線並提高藥物開發成功概率的研究平台。</p>
<p>Aska Pharmaceutical 在滿足現實臨牀需求方面積累了豐富經驗，特別是在女性健康領域，並開發了一個專注於未滿足醫療需求的產品組合。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>由 GlobalData 提供</p>
<p>瞭解更多關於戰略情報</p>
<p>該公司開發了廣泛的產品，以支持女性在不同生命階段的需求。</p>
<p>此次合作將結合帝人制藥的先進藥物發現技術與 Aska Pharmaceutical 在婦科疾病評估方面的臨牀專業知識。</p>
<p>兩家公司共同的目標是提供創新治療方案，以改善患有婦科疾病女性的生活質量。</p>
<p>Aska Pharmaceutical 專注於三個領域：泌尿科、內科（消化內科和甲狀腺）以及婦產科。</p>
<p>帝人在全球範圍內提供高性能材料和醫療解決方案，與合作伙伴共同提供符合其長期願景的解決方案。</p>
<p>帝人最近向日本藥品和醫療器械管理局提交了申請，尋求對 lonapegsomatropin（生長激素的前藥）的生產和營銷批准，該藥物每週給藥一次。</p>

3401

4886

<p>帝人制藥與阿斯卡製藥達成聯合研究協議，共同開發用於婦科疾病的小分子藥物候選物。此次合作旨在利用帝人公司在計算機輔助藥物設計和人工智能方面的專業知識，加速早期藥物發現。兩家公司將專注於識別與特定分子靶點相互作用的化合物，並對其進行優化，以提高療效和安全性。該合作伙伴關係旨在改善患有婦科疾病女性的生活質量，將帝人先進的藥物發現技術與阿斯卡的臨牀專業知識相結合</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-17-02-2026-shutterstock_2249605625-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-17-02-2026-shutterstock_2249605625-430x241.jpg"/></p>
<p>Both companies share the goal of providing innovative treatments to improve quality of life for women with gynaecological conditions. Credit: Peakstock / Shutterstock.com.</p>
<div class="lb-trans"><p>兩家公司共同的目標是提供創新治療方案，以改善患有婦科疾病女性的生活質量。圖片來源：Peakstock / Shutterstock.com。</p>
</div><p>Teijin Pharma has signed a joint research agreement with Tokyo-based Aska Pharmaceutical to develop small-molecule drug candidates for gynaecological diseases.</p>
<div class="lb-trans"><p>帝人制藥與總部位於東京的 Aska Pharmaceutical 簽署了聯合研究協議，旨在開發針對婦科疾病的小分子藥物候選物。</p>
</div><p>The collaboration aims to expedite early-stage drug discovery focused on innovative therapeutics, using Teijin Pharma’s expertise in computer-aided drug design (CADD) and AI.</p>
<div class="lb-trans"><p>此次合作旨在加速早期藥物發現，專注於創新療法，利用帝人制藥在計算機輔助藥物設計（CADD）和人工智能方面的專業知識。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - GSK-4381562 in Endometrial Cancer</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - GSK-4381562 在子宮內膜癌中的應用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - INCB-123667 in Endometrial Cancer</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - INCB-123667 在子宮內膜癌中的應用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>Under the agreement, both companies will focus on identifying “hit” compounds that interact with specific molecular targets.</p>
<div class="lb-trans"><p>根據協議，兩家公司將專注於識別與特定分子靶點相互作用的 “命中” 化合物。</p>
</div><p>These initial compounds will undergo further optimisation to establish the desired efficacy, pharmacokinetic properties, and safety required for potential drug development.</p>
<div class="lb-trans"><p>這些初步化合物將進一步優化，以確定潛在藥物開發所需的有效性、藥代動力學特性和安全性。</p>
</div><p>Teijin Pharma is advancing its drug candidate discovery process by enhancing simulation accuracy and predictive modelling, resulting in a research platform that shortens timelines and raises the probability of success in drug development.</p>
<div class="lb-trans"><p>帝人制藥通過提高模擬準確性和預測建模，推進其藥物候選物發現過程，從而建立一個縮短時間線並提高藥物開發成功概率的研究平台。</p>
</div><p>Aska Pharmaceutical brings experience grounded in addressing real-world clinical needs, particularly in women’s health, and has developed a portfolio focused on unmet medical requirements in the field.</p>
<div class="lb-trans"><p>Aska Pharmaceutical 在滿足現實臨牀需求方面積累了豐富經驗，特別是在女性健康領域，並開發了一個專注於未滿足醫療需求的產品組合。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>The company has developed a wide range of products to support women at various stages of life.</p>
<div class="lb-trans"><p>該公司開發了廣泛的產品，以支持女性在不同生命階段的需求。</p>
</div><p>The partnership will combine Teijin Pharma’s advanced drug discovery technologies with Aska Pharmaceutical’s clinical expertise in gynaecological disease evaluation.</p>
<div class="lb-trans"><p>此次合作將結合帝人制藥的先進藥物發現技術與 Aska Pharmaceutical 在婦科疾病評估方面的臨牀專業知識。</p>
</div><p>Both companies share the goal of providing innovative treatments to improve the quality of life for women with gynaecological conditions.</p>
<div class="lb-trans"><p>兩家公司共同的目標是提供創新治療方案，以改善患有婦科疾病女性的生活質量。</p>
</div><p>Aska Pharmaceutical specialises in three areas: urology, internal medicine (gastroenterology and thyroid), and obstetrics and gynaecology.</p>
<div class="lb-trans"><p>Aska Pharmaceutical 專注於三個領域：泌尿科、內科（消化內科和甲狀腺）以及婦產科。</p>
</div><p>Teijin operates across high-performance materials and healthcare solutions worldwide, working with partners to deliver solutions aligned with its long-term vision.</p>
<div class="lb-trans"><p>帝人在全球範圍內提供高性能材料和醫療解決方案，與合作伙伴共同提供符合其長期願景的解決方案。</p>
</div><p>Teijin recently submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency seeking manufacturing and marketing approval for lonapegsomatropin, a prodrug of somatropin, which is administered once weekly.</p>
<div class="lb-trans"><p>帝人最近向日本藥品和醫療器械管理局提交了申請，尋求對 lonapegsomatropin（生長激素的前藥）的生產和營銷批准，該藥物每週給藥一次。</p>
</div>

帝人公司與 Aska 製藥公司將共同開發婦科藥物